This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Pulmonary Diseases  • Pneumonia  • Infectious Diseases, Other  • Pediatrics  • Neonatology and Infant Care  • Hemangiomas  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic

Mandi L. Maronn, MD; Timothy Corden, MD; Beth A. Drolet, MD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Infantile hemangiomas are common, benign, and self-limited tumors of infancy. A recent multi-institution study found that 30% of infants experience complications related to their hemangioma.¹ Of those seen in tertiary medical centers, 12% require treatment with oral corticosteroids.¹ Ulceration, ocular compromise, and risk of permanent disfigurement are the most frequent reasons for intervention. There are no agents approved by the US Food and Drug Administration for the treatment of hemangiomas, but current practice includes the use of high-dose corticosteroids. The beneficial effects of corticosteroids were first described in the 1960s, and despite decades of treatment, the literature consists primarily of case reports and small case series. The effects of steroid administration to such a young patient population have not been systematically evaluated. High-dose corticosteroids are an independent risk factor for the development of Pneumocystis carinii pneumonia (PCP).² However, most . . . [Full Text of this Article]

Report of a Case


Comment

AUTHOR INFORMATION